Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ ...
For the first time Australian researchers have identified how exposure to smoking may cause a deadly lung disease that claims thousands of lives every year.
Dual blocking SHP2 and FGFR2 can not only promote the targeted tumor-killing effects and overcome FGFR2 inhibitor resistance caused by feedback activation, but also activate T cell-mediated anti-tumor ...
ImmunityBio, Inc. , a leading immunotherapy company, today announced significant progress in its ongoing discussions with the U.S. Food and Drug Administration (FDA) regarding three areas of its ...
The virus often mutates by simply deleting small pieces of its genetic code. The mutations "disguise" the virus from antibodies. Zachary Levi calls for California leadership to be 'held ...
We work right across the cancer research pathway with strengths ranging from cell biology to healthcare research. We aim to nurture the thought leaders of today and tomorrow through the provision of ...
and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells ...
This strategy not only intensifies immune responses but also improves the durability of treatment by overcoming tumor immune escape mechanisms. Despite the immense potential of VLPs in cancer ...
When liver cells become stressed or damaged due to conditions like MASH, FBP1 helps activate tumor-suppressing mechanisms. However, the team found that most liver cancers in their study had developed ...